Invasive mold infections in chronic granulomatous disease: A 25-year retrospective survey

Clinical Infectious Diseases

Volumn 53, Issue 12, 2011, Pages

  Blumental, Sophie ^a,b   Mouy, Richard ^a   Mahlaoui, Nizar ^a,c   Bougnoux, Marie Elisabeth ^d   Debré, Marianne ^a   Beauté, Julien ^c   Lortholary, Olivier ^a,c,e,f   Blanche, Stéphane ^a,f   Fischer, Alain ^a,c,f  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

^c French National Reference Centre for PID (CEREDIH)   (France)

^d Department of Microbiology ^*  (France)

^e INSTITUT PASTEUR   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCYTOSINE; GAMMA INTERFERON; ITRACONAZOLE; VORICONAZOLE;

ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; CHILD; CHRONIC GRANULOMATOUS DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; FEMALE; HEALTH CARE COST; HEALTH SURVEY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; INFECTION PREVENTION; INVASIVE MOLD INFECTION; MALE; MICROBIOLOGICAL PARAMETERS; MORTALITY; MOULD; MYCOSIS; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT DURATION;

ADOLESCENT; ANTIFUNGAL AGENTS; ASPERGILLUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; FUNGI; GRANULOMATOUS DISEASE, CHRONIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MYCOSES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 81855205252     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir731     Document Type: Review

References (50)

1. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical and clinical features of chronic granulomatous disease.Medicine (Baltimore) 2000; 79:170-200. (Pubitemid 30327531)
2. Heyworth PG, Cross AR, Curnutte JT. Chronic granulomatous disease. Curr Opin Immunol 2003; 15:578-84. (Pubitemid 37130200)
3. Van den berg JM, Van Koppen E, Ahlin A, et al. Chronic granulomatous disease: the European experience. Plos One 2009; 4:e5234.
4. Liese J, Kloos S, Jendrossek V, et al. Long-term follow-up and outcome of 39 patients with chronic granulomatous disease. J Pediatr 2000; 137:687-93.
5. Wolach B, Gavrieli R, de Boer M, et al. Chronic granulomatous disease in Israel: clinical, functional and molecular studies of 38 patients. Clin Immunol 2008; 129:103-14.
6. Kuhns DB, Alvord WG, Heller T, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010; 363:2600-10.
7. Johnston RB Jr, McMurray JS. Chronic familial granulomatosis: report of 5 cases and review of the literature. Am J Dis Child 1967; 114:370-8.
8. Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79:155-69. (Pubitemid 30327530)
9. Kobayashi S, Murayama S, Takanashi S, et al. Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan. Eur J Pediatr 2008; 167:1389-94.
10. Cale CM, Jones AM, Goldblatt D. Follow up of patients with chronic granulomatous disease diagnosed since 1990. Clin Exp Immunol 2000; 120:351-5. (Pubitemid 30304233)
11. Martire B, Rondelli R, Soresina A, et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin Immunol 2008; 126:155-64.
12. Jones LB, McGrogan P, Flood TJ, et al. Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol 2008; 152:211-18. (Pubitemid 351520920)
13. Margolis DM, Melnick DA, Alling DW, Gallin JI. Trimethoprimsulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 1990; 162:723-6. (Pubitemid 20266166)
14. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med 1991; 324:509-16.
15. Gallin J, Zarember K. Lessons about the pathogenesis and management of aspergillosis from studies in chronic granulomatous disease. Trans Am Clin Climatol Assoc 2007; 118:175-85.
16. Seger RA. Modern management of chronic granulomatous disease. Br J Haematol 2008; 140:255-66.
17. Seger RA, Gungor T, Belohradsky BH, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood 2002; 100:4344-50. (Pubitemid 35429672)
18. Horwitz ME, Barret AJ, brown MR, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and t-cell depleted hematopoietic allograft. N Engl J Med 2001; 344:881-8. (Pubitemid 32224396)
19. Segal BH, De Carlo ES, Kwon-Chung KJ, et al. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 1998; 77:345-54. (Pubitemid 28449835)
20. Dotis J. Roilides E. Osteomyelitis due to Aspergillus spp in patients with chronic granulomatous disease: comparison of Aspergillus nidulans and Aspergillus fumigatus. Int j Infect Dis 2004; 8:103-10. (Pubitemid 38166076)
21. Segal B, Romani L. Invasive aspergillosis in chronic granulomatous disease. Med Mycol 2009; 18:S1-S9.
22. Jabado N, Casanova JL, Haddad E, et al. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin Infect Dis 1998; 27:1437-41. (Pubitemid 29242418)
23. Mouy R, Veber F, Blanche S, et al. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J Pediatr 1994; 125:998-1003. (Pubitemid 24379140)
24. Gallin JI, Alling DW, Malech HL, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 2003; 348:2416-22. (Pubitemid 36682820)
25. Herbrecht R, Denning DW, Patterson TW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15. (Pubitemid 34851833)
26. Maertens J, Meersseman W, Van Bleyenbergh P. New therapies for fungal pneumonia. Curr Opin Infect Dis 2009; 22:183-90.
27. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Disease Society of America. Clin Infect Dis 2008; 46:327-60. (Pubitemid 351265310)
28. Wheat LJ, Walsh TJ. Diagnosis of invasive aspergillosis by galactomannan antigenemia, detection using an enzyme immunoassay. Eur J Clin Microbiol Infect Dis 2008; 27:245-51.
29. Senn L, Robinson JO, Schmidt S, et al. 1,3-beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2004; 39:199-205.
30. The French national registry of primary immunodeficiency diseases. Clin Immunol 2010; 135:264-72.
31. Gathmann B, Grimbacher B, Beauté J, et al. The European internetbased patient and research database for primary immunodeficiencies: results 2006-2008. Clin Exp Immunol 2009; 157:S13-14.
32. Beauté J, Obenga G, Le mignot L, et al. Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France. Pediatr Infect Dis J 2011; 30:57-62.
33. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-21.
34. Verweij PE, Warris A, Weemaes CM. Preventing fungal infections in chronic granulomatous disease. N Engl J Med 2003; 349:1190-1. (Pubitemid 37122338)
35. Denning DW, Venkateswarlu K, Oakley KL, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41:1364-8. (Pubitemid 27231443)
36. Verweij P, Weemaes M, Curfs J, et al. Failure to detect circulating Aspergillus markers in a patient with chronic granulomatous disease and invasive aspergillosis. J Clin Microbiol 2000; 38:3900-1.
37. Walsh TJ, Schaufele RL, Sein T, et al. Reduced expression of galactomannan antigenemia in patientswith invasive aspergillosis and chronic granulomatous disease or Job syndrome [abstract 345]. In: Infectious Disease Society of America 40th Annual Meeting. Chicago, IL, 2002.
38. Dennis CG, Greco WR, Brun Y, et al. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/-mouse model of chronic granulomatous disease. Antimicrob Agents Chemother 2006; 50:422-7. (Pubitemid 43190948)
39. Kontoyiannis DP, Lewis RE, May GS, Osherov N, Rinaldi MG. Aspergillus nidulans is frequently resistant to amphotericin B. Mycoses 2002; 45:406-7. (Pubitemid 35357014)
40. Snelders E, Van der Lee HAL, Kujipers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. Plos Med 2008; 5:e219.
41. Balajee SA, Kano R, Baddley JW, et al. Molecular identfication of Aspergillus species collected for the Transplant-associated Infection Surveillance Network. J Clin Microbiol 2009; 47:3138-41.
42. Balajee SA, Gribskov JL, Hanley E, et al. Aspergillus lentulus sp.nov., a new sibling species of A.fumigatus. Eukaryot Cell 2005; 4:1705-12.
43. Verweij PE, Varga J, Houbraken J, et al. Emericella quadrilineata as cause of invasive aspergillosis. Emerg Infect Dis 2008; 14:566-72. (Pubitemid 351520857)
44. Cohen MS, Isturiz RE, Malech HL, et al. Fungal infection in chronic granulomatous disease: the importance of the phagocyte in defense against fungi. Am J Med 1981; 71:59-66. (Pubitemid 12254714)
45. Van 't Hek LG, Verweij PE, Weemaes CM, et al. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Respir Crit Care Med 1998; 157:1694-6.
46. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21:240-8. (Pubitemid 34214142)
47. Segal BH, Barnhart L, Anderson V, et al. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 2005; 40:1684-8. (Pubitemid 40720823)
48. Gungor T, Halter J, Klink A, et al. Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients. Transplantation 2005; 79:1596-606. (Pubitemid 40847593)
49. Soncini E, Slatter MA, Jones LB, et al. Unrelated donor and HLAidentical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol 2009; 145:73-83.
50. Seger RA. Hematopoietic stem cell transplantation for chronic granulomatous disease. Immunol Allergy Clin North Am 2010; 30:195-208.